title: Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy.
abstract: Traditional therapy of acute myelogenous leukemia has not cured more than 10% of patients and, of acute lymphoblastic leukemia not more than 30% of adults. In part, this is due to the lack of agents effective enough to induce remissions of such quality that cure is possible. The introduction of mitoxantrone and its use in high dose with high-dose cytarabine for induction therapy, raises the possibility of an increased cure rate of acute myelogenous leukemia and acute lymphoblastic leukemia.
authors.affiliation: New York Medical College, Department of Medicine, Valhalla 10595.
authors.forename: Z A
authors.initials: ZA
authors.lastname: Arlin
authors.forename: T
authors.initials: T
authors.lastname: Ahmed
authors.forename: A
authors.initials: A
authors.lastname: Mittelman
authors.forename: P
authors.initials: P
authors.lastname: Cook
authors.forename: C A
authors.initials: CA
authors.lastname: Puccio
authors.forename: L
authors.initials: L
authors.lastname: Helson
authors.forename: H G
authors.initials: HG
authors.lastname: Chun
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002470:Cell Survival / Q000187:drug effects; D002648:Child; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000187:drug effects; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous